Jedd D Wolchok Selected Research

Vaccines

1/2024	APR-246 increases tumor antigenicity independent of p53.
6/2023	Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
1/2021	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
1/2017	Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.
1/2015	The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.
5/2014	Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
12/2011	Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.
10/2011	Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
4/2011	Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
9/2010	Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jedd D Wolchok Research Topics

Disease

256	Neoplasms (Cancer) 05/2024 - 01/2002
203	Melanoma (Melanoma, Malignant) 05/2024 - 01/2002
17	Disease Progression 11/2023 - 01/2008
13	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2008
11	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023 - 08/2015
11	Experimental Melanoma 11/2021 - 05/2003
10	Brain Neoplasms (Brain Tumor) 01/2018 - 09/2003
9	Body Weight (Weight, Body) 10/2019 - 08/2010
7	Lung Neoplasms (Lung Cancer) 10/2023 - 04/2015
7	Inflammation (Inflammations) 01/2021 - 03/2014
7	Prostatic Neoplasms (Prostate Cancer) 04/2019 - 10/2003
6	Carcinoma (Carcinomatosis) 11/2023 - 05/2010
6	COVID-19 10/2022 - 01/2020
6	Testicular Neoplasms (Testicular Cancer) 01/2021 - 02/2005
6	Colitis 11/2018 - 01/2014
5	Uveal melanoma 05/2022 - 04/2011
5	Breast Neoplasms (Breast Cancer) 12/2016 - 04/2004
5	Vitiligo 07/2014 - 07/2002
4	Bites and Stings (Sting) 01/2023 - 05/2017
4	Exanthema (Rash) 01/2023 - 05/2012
4	Communicable Diseases (Infectious Diseases) 11/2017 - 01/2002
3	Renal Cell Carcinoma (Grawitz Tumor) 11/2023 - 01/2018
3	Pancreatic Neoplasms (Pancreatic Cancer) 06/2023 - 11/2017
3	Infections 05/2017 - 12/2012
3	Hypersensitivity (Allergy) 01/2017 - 07/2010
3	Fatigue 08/2015 - 05/2012
3	Sarcoma (Soft Tissue Sarcoma) 03/2005 - 11/2003
2	Cytokine Release Syndrome 12/2023 - 01/2023
2	Cardiotoxicity 12/2023 - 10/2018
2	Stomach Neoplasms (Stomach Cancer) 11/2023 - 07/2013
2	Adenocarcinoma of Lung 10/2023 - 01/2018

Drug/Important Bio-Agent (IBA)

101	IpilimumabIBA 05/2024 - 01/2008
55	Immune Checkpoint InhibitorsIBA 03/2024 - 07/2013
40	NivolumabIBA 05/2024 - 07/2013
38	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 01/2002
38	AntibodiesIBA 10/2023 - 07/2002
34	AntigensIBA 01/2023 - 01/2002
29	Monoclonal AntibodiesIBA 10/2019 - 11/2003
26	pembrolizumabIBA 11/2023 - 07/2013
22	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2011
21	VaccinesIBA 01/2024 - 01/2002
20	Proteins (Proteins, Gene)FDA Link 10/2022 - 04/2004
19	DNA VaccinesIBA 08/2017 - 01/2002
15	Neoplasm Antigens (Tumor Antigens)IBA 01/2023 - 01/2003
15	CTLA-4 AntigenIBA 01/2018 - 12/2008
14	Peptides (Polypeptides)IBA 10/2022 - 05/2003
14	Monophenol Monooxygenase (Tyrosinase)IBA 08/2017 - 04/2003
14	AutoantigensIBA 05/2014 - 10/2002
12	Programmed Cell Death 1 ReceptorIBA 10/2023 - 07/2013
11	B7-H1 AntigenIBA 10/2023 - 11/2016
10	Differentiation AntigensIBA 09/2010 - 05/2003
8	RNA (Ribonucleic Acid)IBA 10/2023 - 05/2003
8	GlucocorticoidsIBA 10/2021 - 04/2009
8	InterferonsIBA 01/2021 - 08/2015
7	Blocking AntibodiesIBA 01/2021 - 01/2011
7	EpitopesIBA 11/2017 - 05/2003
7	Temozolomide (Temodar)FDA LinkGeneric 06/2014 - 09/2003
6	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2023 - 04/2013
6	EnzymesIBA 01/2023 - 08/2011
6	Dacarbazine (DIC)FDA LinkGeneric 04/2015 - 02/2004
5	CytokinesIBA 05/2024 - 09/2006
5	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 10/2021 - 04/2009
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2014 - 02/2009
4	dabrafenibIBA 12/2023 - 04/2017
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2023 - 01/2002
4	Cancer VaccinesIBA 01/2022 - 12/2008
4	Immunoglobulin G (IgG)IBA 02/2021 - 09/2006
4	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 11/2020 - 08/2011
4	LigandsIBA 07/2015 - 05/2006
4	Imatinib Mesylate (Gleevec)FDA Link 05/2015 - 05/2011
4	HLA-A*02:01 antigenIBA 10/2010 - 11/2007
4	Thalidomide (Thalomid)FDA Link 03/2007 - 09/2003
3	Immunomodulating AgentsIBA 01/2024 - 02/2015
3	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2023 - 05/2017
3	Protein Subunit VaccinesIBA 10/2022 - 07/2010
3	Alkylating AgentsIBA 10/2021 - 05/2009
3	LipidsIBA 01/2021 - 11/2015
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 11/2013
3	Interferon-gamma (Interferon, gamma)IBA 01/2017 - 02/2009
3	Glycoproteins (Glycoprotein)IBA 11/2016 - 08/2010
3	tyrosinase-related protein-1IBA 11/2016 - 05/2006
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2016 - 06/2011
3	Complement System Proteins (Complement)IBA 01/2016 - 05/2003
3	Interferon Type IIBA 08/2015 - 01/2014
3	Interleukin-2 (IL2)IBA 01/2015 - 04/2011
3	Therapeutic UsesIBA 05/2014 - 09/2010
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2013 - 11/2007
3	Oncogene Proteins (Oncogene Protein)IBA 06/2012 - 07/2010
2	eprenetapoptIBA 01/2024 - 01/2022
2	trametinibIBA 12/2023 - 10/2023
2	tributyl phosphate (TBP)IBA 11/2023 - 11/2017
2	Small Cytoplasmic RNAIBA 10/2023 - 01/2022

Therapy/Procedure

130	Therapeutics 10/2023 - 01/2002
105	Immunotherapy 12/2023 - 01/2002
13	Drug Therapy (Chemotherapy) 10/2023 - 06/2005
10	Radiotherapy 12/2021 - 06/2010
9	Aftercare (After-Treatment) 01/2020 - 11/2003
5	Immunomodulation 01/2017 - 03/2013
4	Ligation 11/2013 - 05/2006
3	Time-to-Treatment 01/2020 - 10/2015